Journal article
T.I.4 Splice manipulation therapies: Opportunities and challenges
Neuromuscular Disorders, Vol.18(9-10), pp.831-831
2008
Abstract
A variety of oligomer chemistries allow gene expression to be modified via several distinct mechanisms: specific degradation through RNaseH action or gene silencing, translation blockade or redirection of splicing patterns, including exon excision or inclusion. Protein truncating mutations in the huge dystrophin gene typically lead to the most common and serious form of childhood muscle wasting, Duchenne muscular dystrophy (DMD). Exon skipping strategies can be developed to by-pass most DMD-causing mutations in the dystrophin gene transcript, in essence a form of molecular by-pass surgery allowing production of a protein of potentially near normal function. The distribution and complexity of dystrophin gene expression that posed great challenges for gene repair or replacement, may be regarded as positive attributes for induced exon skipping. Clinical trials are currently underway to assess some safety aspects, while addressing one of the most common sub-types of deletion mutation. These trials will provide proof-of-principle for targeted exon skipping in human skeletal muscle, an essential pre-requisite for subsequent systemic applications. Many different oligomers have been optimised in vitro, in preparation for subsequent application to different dystrophin mutations, once efficacy has been demonstrated by exon 51 skipping. Should dystrophin exon skipping prove to be beneficial in reducing the severity and progression of DMD, these studies may provide a useful platform to launch splice-intervention therapies for many different neuromuscular conditions, including suppression of abnormal splicing, enhancing exon 7 inclusion in the SMN2 gene transcript for SMA Type 1, and correction of abnormal splicing events in Myotonic Dystrophy Type 1.
Details
- Title
- T.I.4 Splice manipulation therapies: Opportunities and challenges
- Authors/Creators
- S. Wilton (Author/Creator) - The University of Western AustraliaS. Fletcher (Author/Creator) - The University of Western Australia
- Publication Details
- Neuromuscular Disorders, Vol.18(9-10), pp.831-831
- Publisher
- Elsevier BV
- Identifiers
- 991005540353007891
- Copyright
- © 2008 Published by Elsevier B.V.
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
- Note
- Abstract: 13th International Congress of the World Muscle Society, Newcastle Upon Tyne, UK. 29 September - 2 October 2008
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
29 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Citation topics
- 1 Clinical & Life Sciences
- 1.255 Musculoskeletal Disorders
- 1.255.628 Duchenne Muscular Dystrophy
- Web Of Science research areas
- Clinical Neurology
- Neurosciences
- ESI research areas
- Neuroscience & Behavior